Corrigendum to ‘Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)’ [European Journal of Cancer 152 (2021) 116-128]
Year: 2021
Type: erratum
Source: European Journal of Cancer
Authors: Helen Gogas, Reinhard Dummer, Paolo A. Ascierto, Ana Arance, Mario Mandalà, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsová, Ralf Gutzmer, Vanna Chiarion Sileni, Caroline Dutriaux, Naoya Yamazaki, Carmen Loquai, Paola Queirolo, Groot J. de Willem, Abir T. Sellier, Jeanne Suissa, Juliette Murris, Ashwin Gollerkeri, Caroline Robert, Keith T. Flaherty
Institutions: National and Kapodistrian University of Athens, University Hospital Zurich, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Hospital Clínic de Barcelona, University of Perugia, National Institute of Oncology, University of Tübingen, Essen University Hospital, Deutsches Konsortium für Translationale Krebsforschung, Charles University, Medizinische Hochschule Hannover, Istituto Oncologico Veneto, Centre Hospitalier Universitaire de Bordeaux, Hôpital Saint-André, National Cancer Center Hospital, University Medical Center of the Johannes Gutenberg University Mainz, Ospedale Policlinico San Martino, European Institute of Oncology, Isala, Pierre Fabre (France), Pfizer (United States), Institut Gustave Roussy, Massachusetts General Hospital
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W3208751815